IQVIA Holdings, Inc. (IQV) Stock Analysis
Healthcare · Diagnostics & Research
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions,... Read more
TrendMatrix rates IQVIA Holdings, Inc. (IQV) as Sell with moderate confidence. The stock trades at $165.64 with +21.2% upside to the $200.76 price target. Overall score: 5.7/10 across 10 analysis dimensions. Reward/risk ratio: 4.2:1.
Passes 3/5 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags). Fails on weak momentum and death cross (50MA < 200MA). Suitability: aggressive.
Investment Thesis
Fundamentals
Frequently Asked Questions
TrendMatrix rates IQVIA Holdings, Inc. (IQV) as Sell with moderate confidence. Score 5.7/10.
Take-profit target: $200.76 (+21.2% upside). Reward/risk ratio: 4.2:1. Stop-loss: $157.35.
V7 low-quality RISK_OFF penalty: -0.5 (Q=5.5); Leverage penalty (D/E 2.5): -1.5; Negative momentum.
IQVIA Holdings, Inc. trades at a P/E of 21.3 (forward 11.9). TrendMatrix value score: 7.2/10. Verdict: Sell.
30 analysts cover IQV with a consensus score of 4.1/5. Average price target: $236.
What does IQVIA Holdings, Inc. do?IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life...
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. is based in Durham, North Carolina.